Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 18/20 | 0.62 |
| ▸ | KDR | P35968 | 15/20 | 0.62 |
| ▸ | FYN | P06241 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2911187 | 0.92 | FGFR3 (0.59) | FGFR3KDR | |
| SCHEMBL10138787 | 0.91 | FGFR3 (0.61) | FGFR3KDRFYN | |
| SCHEMBL563338 | 0.90 | FGFR3 (0.57) | FGFR3KDRFYN | |
| SCHEMBL10171476 | 0.89 | FGFR3 (0.56) | FGFR3KDRFYN | |
| Hydrochloric Acid SCHEMBL562952 | 0.88 | FGFR3 (0.55) | FGFR3KDRFYN | |
| SCHEMBL563885 | 0.87 | HPGD (0.58) | FGFR3KDR | |
| SCHEMBL3590921 | 0.84 | FGFR3 (0.56) | FGFR3KDR | |
| SCHEMBL13407665 | 0.84 | KDR (0.61) | FGFR3KDR | |
| SCHEMBL3581751 | 0.84 | FGFR3 (0.61) | FGFR3KDRFYN | |
| SCHEMBL13407728 | 0.83 | FGFR3 (0.59) | FGFR3KDRFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2203449-B1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2016-04-27 | — | — | EP | disclosed |
| US-8859582-B2 | Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2014-10-14 | — | — | US | disclosed |
| US-8859582-B2 | Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2014-10-14 | — | — | US | disclosed |
| US-20120035152-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2012-02-09 | — | — | US | disclosed |
| US-20120035152-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2012-02-09 | — | — | US | disclosed |
| US-8071614-B2 | Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-8071614-B2 | Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-8071614-B2 | Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-20100286113-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286113-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286113-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286113-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, BMX, BTK | FGFR3 238/4885KDR 1036/4885FYN 47/4885 |
| US-20120035152-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, BMX, BTK | FGFR3 238/4885KDR 1036/4885FYN 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.